Inicio / Oncología / Abstracts de oncología / Endocrine treatment versus…

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

0 / 5 (0 votos)
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

The Lancet Oncology

Fecha de publicación: 4 September 2019

DOI: https://doi.org/10.1016/S1470-2045(19)30420-6

Autores: Mario Giuliano, MD., Francesco Schettini, MD.,
Carla Rognoni, PhD., Manuela Milani, MD., Prof Guy Jerusalem, MD., Thomas Bachelot, MD., et al.

Background: Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line or second-line treatments, or both, based on chemotherapy and on hormone therapy have been scarcely investigated in head-to-head randomised controlled trials, we aimed to compare these two different approaches.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.